SavedAdd your journal

Journals / Journal of Clinical and Analytical Medicine / 2013 / Cilt: 4 - Sayı: 5

PPI Kullanımının clostridium difficile serum antijen değerlerine olan etkisi

The Effects of PPI use on clostridium difficile serum antigen levels

Sinan KOCATÜRK
Selda DEMİRTAŞ
Rabia ŞEKER
Hande EZERARSLAN
Güçlü Kaan BERİAT
Pages
372–376
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The pre-treatment mean valueof serum Clostridium Difficile Ag was 140.56±11.74, while it was seen thatthe same value became 114.94±10.70 after the three-months treatment (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To evaluate the effects of proton-pump inhibitor (PPI) use on distrub- tion of intestinal flora by measuring serum Clostridium Difficile antigen levels before and at the end of a three-months treatment in patients with Laryn- gopharyngeal reflux (LFR) treatment.
📊
Key Findings & Data:Material and Method: The study covers 32 patients with LFR, out of which 24 were female (75%) and 8 were male (25%).
💡
Conclusion & Impact:The pre-treatment mean valueof serum Clostridium Difficile Ag was 140.56±11.74, while it was seen thatthe same value became 114.94±10.70 after the three-months treatment (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: To evaluate the effects of proton-pump inhibitor (PPI) use on distrub- tion of intestinal flora by measuring serum Clostridium Difficile antigen levels before and at the end of a three-months treatment in patients with Laryn- gopharyngeal reflux (LFR) treatment. Material and Method: The study covers 32 patients with LFR, out of which 24 were female (75%) and 8 were male (25%). The mean age of the patients was 34.13 ± 11.59. All patients included in the study were administered Lansoprazole 30 mg tablets perorally before meals and twice a day for treatment. Reflux Symptom Index (RSI), Reflux Finding Score (RFS), white blood cell count, CRP and serum Clostridium Difficile toxin A, B measurement results were comparatively evaluated through the blood serum samples drawn from the patients before and at the end of the three-months treatment. Results: While the mean values of pre-treatment RSI and RFI were 20.81±4.05 and 13.31±3.30 respectively, the meanvalues were measured to be 3.41±2.37 and 1.50±1.88 respectively following the three-months treatment (p< 0.05). The pre-treatment mean valueof serum Clostridium Difficile Ag was 140.56±11.74, while it was seen thatthe same value became 114.94±10.70 after the three-months treatment (p

Özet

Amaç: Larengofarengeal Reflü (LFR) hastalığının tedavisi amacıyla Proton pompa inhibitörü (PPİ) kullanan hastalarda tedavi öncesi ve üç aylık tedavinin sonunda serum Clostridium Difficile antijen miktarı ölçülerek PPİ kullanımının serum Clostridium Difficile serum antijen miktarı üzerindeki etkisinin değerlendirilmesi. Gereç ve Yöntem: Çalışmaya LFR hatalığı tespit edilen 32 hasta ( 24 ( % 80)’ü kadın, 8 (% 20)’i erkek) dahil edildi. Hastaların yaş ortalaması 34.13 ± 11.59 idi. Çalışmaya dahil edilen tüm hastalara tedavi için günde iki kez yemeklerden önce alınacak şekilde lansoprazol 30 mg tablet peroral olarak başlandı. Tedavi öncesinde ve üç aylık tedavinin sonunda hastaların LFR şiddeti Reflü Semptom İndeksi ( RSI) ve RBS ( Reflü Bulgu Skoru) kullanılarak değerlendirildi. Ayrıca hastalardan tedavi öncesi ve üç aylık tedavinin sonunda alınan kan serum örneklerinde beyaz küre, CRP, sedimantasyonve serum Clostridium Difficile toxin A, B ölçümleri yapılarak karşılaştırmalı olarak değerlendirildi. Bulgular: Tedavi öncesi RSI ve RBS ortalamaları sırasıyla 20.81±4.05 ve 13.31±3.30 iken, üç aylık tedavi sonrasında bu ortalamalar sırasıyla 3.41±2.37 ve 1.50±1.88 olarak tespit edildi ( p 0,05). Tartışma: Elde ettiğimiz sonuçlara göre, proton pompa inhibitörü kullanan hastaların Clostridium difficilie toxin A, B serum antijen düzeylerinde istatistiksel olarak anlamlı bir düşüş olduğunu görüldü.

🔖

Cite This Article

KOCATÜRK, S., DEMİRTAŞ, S., ŞEKER, R., EZERARSLAN, H., BERİAT, G. K. (2022). PPI Kullanımının clostridium difficile serum antijen değerlerine olan etkisi. Journal of Clinical and Analytical Medicine, Cilt: 4 - Sayı: 5, 372–376. https://ajindex.com/articles/561312

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Cherry J, Margulies SI: Contact Ulcer of the Larynx. Laryngoscope. 1968;78(11):1937-40
  2. Malcomson KG. Globus Hystericus vel Pharyngis (A Reconnaissance of Proximal Vagal Modalities ). J Laryngol Otol. 1968;82(3):219-30
  3. Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope. 1991;101(4 Pt 2 Suppl 53):1- 78
  4. Koufman JA. Low-acid diet for recalcitrant laryngopharyngeal reflux: therapeutic benefits and their implications. Ann Otol Rhinol Laryngol. 2011;120(5):281-7
  5. Chiba T, Kudara N, Abiko Y, et al. Effects of Proton Pump Inhibitors in Patients with Laryngopharyngeal Reflux Disease. Hepatogastroenterology. 2011 14;58(110-111):1580-1582
  6. Sachs G, Shin JM, Howden CW. The clinical pharmacology of proton pump inhibi- tors. Aliment Pharmacol Ther. 2006;23(2):2–8
  7. Hunfeld N GM, Geus WP, Kuipers EJ. Rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther. 2007;25(1):39-46
  8. Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population- based study. Clin Infect Dis. 2006;43(10):1272-6
  9. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008;103(9):2308-13
  10. Alcalá L, Martín A, Marín M, Sánchez-Somolinos M, Catalán P, Peláez T, Bouza E; on behalf of the Spanish Clostridium difficile Study Group. The undiagnosed cases of Clostridium difficile infection in a whole nation: where is the problem? Clin Microbiol Infect. 2012. doi: 10.1111
  11. Schmidt ML, Gilligan PH. Clostridium difficile testing algorithms: what is practical and feasible? Anaerobe. 2009;15(6):270-3
  12. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008; 46(1): 12-8
  13. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170(9):772- 8
  14. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol. 2009;15(13):1554-80
  15. Bavishi C, Dupont HL. Systematic r